Xolair 150 MG/ML 1S
Ended Awarded
- Contract number
- SPE2DR26FBTBY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,106
Award facts
- Contract value 100% obligated
- $13,105.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $13,105.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml. This firm fixed-price delivery order, issued on November 12, 2025, with an ultimate completion date of November 24, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents part of the broader $30.3 billion pharmaceutical supply strategy established by the Defense Logistics Agency to support recurring medical supply needs across Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group operates as one of multiple regional prime vendor contractors under this acquisition vehicle, authorized to fulfill diverse pharmaceutical requirements including branded and generic prescription drugs, biologics, and medical consumables. The contractor's established performance on numerous delivery orders spanning oncology treatments, immunosuppressants, vaccines, and specialty pharmaceuticals demonstrates its capability to serve as a critical supplier for military healthcare operations globally. No subcontractors have been identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FBTBY?
SPE2DR26FBTBY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FBTBY worth?
The government has obligated $13,106 on SPE2DR26FBTBY.
Is contract SPE2DR26FBTBY an order under another contract?
Yes. SPE2DR26FBTBY is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTBY competed?
The extent of competition for SPE2DR26FBTBY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award